HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT01568216

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Medication studyAges 18–60Multiple countries
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

Listed locations
Anaheim and 37 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMay 2012
Recruitment status
Terminated
Enrollment listed in the registry
121
Sponsor
Amgen
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Australia, Canada, ...
Age range
From 18 Years to 60 Years
Official registry ID
NCT01568216
Official title
Show the full official title

"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"

Questions about this study?

The HopeStage team will email you.

Loading the security check...

Recruitment & locations

Terminated

Anaheim, United States · Cerritos, United States · Culver City, United States

35 more locations
  • Garden Grove, United States
  • Los Angeles, United States
  • Norwalk, United States
  • San Bernardino, United States
  • Torrance, United States
  • Washington D.C., United States
  • North Miami, United States
  • Atlanta, United States
  • Chicago, United States
  • Marlton, United States
  • Glen Oaks, United States
  • Rochester, United States
  • Raleigh, United States
  • Dayton, United States
  • Houston, United States
  • Glenside, Australia
  • Melbourne, Australia
  • Mount Claremont, Australia
  • Calgary, Canada
  • Penticton, Canada
  • Kingston, Canada
  • Montreal, Canada
  • Takapuna, Auckland, New Zealand
  • Khot'kovo, Russia
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Singapore, Singapore
  • Santander, Spain
  • Barcelona, Spain
  • Cornellà de Llobregat, Spain
  • L'Hospitalet de Llobregat, Spain
  • Madrid, Spain
  • Valencia, Spain
  • Russia
Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Amgen.

Does this study involve medication?

Yes. The study involves medication, including AMG 747 and Placebo.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me